IHS Chemical Week

People & Business :: M&A

Xellia expands into the US by acquiring manufacturing plant

8:02 AM MDT | July 7, 2014 | Natasha Alperowicz

Xellia Pharmaceuticals (Copenhagen), a world-leading producer of active pharma ingredients (APIs) and finished dosage forms, today announced it has acquired Fresenius Kabi’s (Lake Zurich, IL) dedicated lyophilized (freeze-dried) vial manufacturing facility at Raleigh, NC. The deal includes a continuous manufacturing and supply agreement with Fresenius Kabi's US arm. Financial details have not been disclosed.   The manufacturing site is located close to the Research Triangle Park and is Xellia’s first facility in the United States, significantly...

This information is only available to Chemical Week subscribers.


Forgot your user ID or password?
Click here to have it sent to you.

Not an IHS Chemical Week subscriber yet?

Here's why you should be:

  • 31 issues of Chemical Week magazine a year in print or digital format
  • Real time news and analysis on chemweek.com 
  • 20+ years of online archives
  • Topical e-newsletters that capture the most impactful events
  • Special issues with a regional or company focus
  • Global Outlook issue

Subscribe now


contact us | about us | privacy policy | sitemap

ihsCopyright © IHS, Inc.All rights reserved.Reproduction in whole or in part without permission is prohibited.

North Asia Russia Southeast Asia China India/Pakistan Middle East Eastern Europe Western Europe Central America Canada USA Australia/New Zealand South America Africa